BONE MARROW-DERIVED CELL BASED THERAPY FOR TYPE 2 DIABETIC PATIENTS

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Though the potential of bone marrow-derived (BMD) cells as a therapeutic entity may be overstated at times, they will likely become an important tool for improving tissue repair and vascular growth. BMD cell therapy can promote angiogenesis, and many complications of diabetes could be mitigated by stimulation of neovascularization. Clinical trials with BMD cells have moved forward, because it has generally been perceived as a low risk therapy. We do not agree that it is low-risk for type 2 diabetic patients. Data from several laboratories suggest that autologous BMD cell therapy may not be effective and could actually be harmful in some diabetic patients. Our ultimate goal is to make BMD cell therapy to induce vascular growth an option for all type 2 diabetic patients. We will test the hypotheses that 1) a subset of BMD cells from type 2 diabetic patients, whose diabetes, and other cardiovascular risk factors are well controlled, are potent stimulators of vascular growth, and 2) the pro-angiogenic activity of BMD cells is diminished by diabetes, and when coupled with co-morbidities, renders BMD cells non- or anti-angiogenic. Our aims are to 1) identify a subset of human type 2 diabetic-derived BMD cells and a method of delivery that in combination potently stimulate vascular growth in diabetic mice; and 2) determine if autologous BMD cell therapy to induced vascular growth may be ineffective or unsafe for some type 2 diabetic patients.